These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 33101007)

  • 1. On the Right Track to Treat Movement Disorders: Promising Therapeutic Approaches for Parkinson's and Huntington's Disease.
    Troncoso-Escudero P; Sepulveda D; Pérez-Arancibia R; Parra AV; Arcos J; Grunenwald F; Vidal RL
    Front Aging Neurosci; 2020; 12():571185. PubMed ID: 33101007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chapter 33: the history of movement disorders.
    Lanska DJ
    Handb Clin Neurol; 2010; 95():501-46. PubMed ID: 19892136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic advances in neural regeneration for Huntington's disease.
    D'Egidio F; Castelli V; Lombardozzi G; Ammannito F; Cimini A; d'Angelo M
    Neural Regen Res; 2024 Sep; 19(9):1991-1997. PubMed ID: 38227527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea.
    Waters CM; Peck R; Rossor M; Reynolds GP; Hunt SP
    Neuroscience; 1988 May; 25(2):419-38. PubMed ID: 2456487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.
    Dexter DT; Carayon A; Javoy-Agid F; Agid Y; Wells FR; Daniel SE; Lees AJ; Jenner P; Marsden CD
    Brain; 1991 Aug; 114 ( Pt 4)():1953-75. PubMed ID: 1832073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgenic mouse models of Parkinson's disease and Huntington's disease.
    Skaper SD; Giusti P
    CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):455-70. PubMed ID: 20522011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease: Autoimmunity and neuroinflammation.
    De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M
    Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of simple and choice reaction time in Parkinson's, Huntington's and cerebellar disease.
    Jahanshahi M; Brown RG; Marsden CD
    J Neurol Neurosurg Psychiatry; 1993 Nov; 56(11):1169-77. PubMed ID: 8229028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
    Harrison IF; Dexter DT
    Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecules to perform big roles: The search for Parkinson's and Huntington's disease therapeutics.
    Pérez-Arancibia R; Cisternas-Olmedo M; Sepúlveda D; Troncoso-Escudero P; Vidal RL
    Front Neurosci; 2022; 16():1084493. PubMed ID: 36699535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases.
    Alexi T; Borlongan CV; Faull RL; Williams CE; Clark RG; Gluckman PD; Hughes PE
    Prog Neurobiol; 2000 Apr; 60(5):409-70. PubMed ID: 10697073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease.
    Alberch J; Pérez-Navarro E; Canals JM
    Brain Res Bull; 2002 Apr; 57(6):817-22. PubMed ID: 12031278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compactotomy in Huntington's chorea.
    Bonelli RM; Kenner L; Gruber A; Reisecker F; Költringer P
    Med Hypotheses; 2001 Oct; 57(4):491-6. PubMed ID: 11601877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial toxins in Basal Ganglia disorders: from animal models to therapeutic strategies.
    Bonsi P; Cuomo D; Martella G; Sciamanna G; Tolu M; Calabresi P; Bernardi G; Pisani A
    Curr Neuropharmacol; 2006 Jan; 4(1):69-75. PubMed ID: 18615133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apathy Profile in Parkinson's and Huntington's Disease: A Comparative Cross-Sectional Study.
    Sousa M; Moreira F; Jesus-Ribeiro J; Marques I; Cunha F; Canário N; Freire A; Januário C
    Eur Neurol; 2018; 79(1-2):13-20. PubMed ID: 29131091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease.
    Rodrigues TM; Jerónimo-Santos A; Outeiro TF; Sebastião AM; Diógenes MJ
    Drugs Aging; 2014 Apr; 31(4):239-61. PubMed ID: 24610720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological approaches to disease-modifying therapies in Parkinson's disease.
    O'Neill MJ; Siemers ER
    Expert Rev Neurother; 2002 Nov; 2(6):819-34. PubMed ID: 19810916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
    Sarkar S; Raymick J; Imam S
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Parkinson's disease : what's on the horizon?
    Wu SS; Frucht SJ
    CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.